Using a new approach to treat painful disc degeneration
Targeting PHLPP to treat interval disc degeneration using surgical and drug delivery methods
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11075896
This study is exploring a new way to help people with chronic back pain caused by disc degeneration by targeting a specific protein to slow down the damage, using a mix of surgery and special medications that can be injected to provide ongoing relief.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11075896 on ClinicalTrials.gov |
What this research studies
This research investigates a novel method to slow down the progression of intervertebral disc degeneration (IDD), a condition that causes chronic back pain. The study focuses on a protein called PHLPP1, which has been found to contribute to the degeneration process. By using a combination of surgical techniques and drug delivery methods, the researchers aim to inhibit PHLPP1 specifically in the affected disc area, potentially reducing inflammation and tissue degradation. The approach includes testing small molecule inhibitors and injectable formulations that can deliver treatment over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults experiencing symptoms of intervertebral disc degeneration.
Not a fit: Patients with acute back injuries or those without signs of disc degeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate chronic back pain and improve the quality of life for patients suffering from disc degeneration.
How similar studies have performed: Other research has shown promising results in targeting similar pathways for treating degenerative conditions, indicating potential for success in this approach.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ILLIEN-JUNGER, SVENJA — EMORY UNIVERSITY
- Study coordinator: ILLIEN-JUNGER, SVENJA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.